Real-World Implementation of RTS,S/AS01E Malaria Vaccine Reduces Severe Malaria by 58%: Evidence from the EPI-MAL-003 Phase 4 Study
Posted inInfectious Diseases news Pediatrics Public Health/Y tế công cộng

Real-World Implementation of RTS,S/AS01E Malaria Vaccine Reduces Severe Malaria by 58%: Evidence from the EPI-MAL-003 Phase 4 Study

This interim analysis of the phase 4 EPI-MAL-003 study demonstrates that the RTS,S/AS01E malaria vaccine significantly reduces severe malaria, malaria-related hospitalizations, and all-cause hospitalizations in real-world clinical settings across Ghana, Kenya, and Malawi, supporting its widespread public health utility.